PRESS RELEASE published on 09/03/2024 at 07:00, 2 years 2 months ago Valneva et Pfizer annoncent de nouvelles données positives de Phase 2 après une vaccination de rappel pour le candidat vaccin contre la maladie de Lyme Valneva et Pfizer rapportent des données positives de Phase 2 pour le candidat vaccin contre la maladie de Lyme, montrant une forte réponse immunitaire post-vaccination de rappel Valneva Phase 2 Maladie De Lyme Pfizer Vaccin
PRESS RELEASE published on 09/03/2024 at 07:00, 2 years 2 months ago Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate Valneva and Pfizer announce positive Phase 2 booster results for Lyme disease vaccine candidate, VLA15-221, showing strong immune response and safety profile, advancing towards Phase 3 trials Valneva Phase 2 Lyme Disease Vaccine Pfizer Immunogenicity
BRIEF published on 08/30/2024 at 11:06, 2 years 2 months ago Franchissement de seuil pour Valneva SE Droits De Vote Franchissement De Seuil Marché Des Actions Valneva SE Groupe Grimaud
BRIEF published on 08/30/2024 at 11:06, 2 years 2 months ago Valneva SE Crosses Threshold Voting Rights Stock Market Valneva SE Threshold Crossing Grimaud Group
PRESS RELEASE published on 08/30/2024 at 11:01, 2 years 2 months ago Franchissement de seuil Déclaration de franchissement de seuil par Groupe Grimaud La Corbière pour VALNEVA SE Déclaration Franchissement De Seuil AMF Valneva SE Groupe Grimaud La Corbière
PRESS RELEASE published on 08/22/2024 at 10:51, 2 years 2 months ago Original-Research: Valneva (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research GmbH hat ein Research Update zu Valneva SE veröffentlicht. Analyst Simon Scholes behält seine Kaufempfehlung bei und bestätigt das Kursziel von EUR 8,60 First Berlin Equity Research Research Update Kaufempfehlung Aktienanalyse Valneva
BRIEF published on 08/20/2024 at 16:06, 2 years 3 months ago First Berlin Equity Research Reiterates Buy Rating for Valneva SE Valneva Equity Research Market Undervaluation H1 Results Lyme Vaccine
BRIEF published on 08/20/2024 at 16:06, 2 years 3 months ago First Berlin Equity Research réitère sa recommandation d'achat pour Valneva SE Valneva Recherche Sur Les Actions Vaccin Contre La Maladie De Lyme Sous-évaluation Du Marché Résultats H1
PRESS RELEASE published on 08/20/2024 at 16:01, 2 years 3 months ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research GmbH updates research on Valneva SE (ISIN: FR0004056851) with a BUY recommendation and EUR 8.60 price target. H1 product sales slightly below consensus but gross margin improving. Valneva maintains full-year guidance First Berlin Equity Research Buy Recommendation Valneva SE EUR 8.60 Price Target H1 Product Sales
BRIEF published on 08/13/2024 at 07:05, 2 years 3 months ago Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates Financial Results Cash Position Revenue Guidance Valneva Vaccine Development
Published on 11/20/2026 at 15:00, 21 hours 19 minutes ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 21 hours 29 minutes ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 22 hours 19 minutes ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 22 hours 49 minutes ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 22 hours 49 minutes ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 12 hours 33 minutes ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 22:39, 13 hours 39 minutes ago ABIVAX: Abivax publie une déclaration concernant le rapport d'un vendeur à découvert
Published on 11/20/2026 at 21:36, 14 hours 42 minutes ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 20:49, 15 hours 29 minutes ago E-PANGO: Jugement du Tribunal Judiciaire de Paris relatif au contentieux avec le groupement RIVP-HENEO-HSF
Published on 11/20/2026 at 18:34, 17 hours 44 minutes ago Déclaration hebdomadaire d'opérations effectuées du 16 au 20 novembre 2026
Published on 11/20/2026 at 18:34, 17 hours 44 minutes ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 18 hours 44 minutes ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 16 au 20 novembre 2026
Published on 11/20/2026 at 17:35, 18 hours 44 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 1 day 17 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR